索拉非尼
网络 索拉非尼;索拉菲尼;多吉美
OBJECTIVE To synthesize sorafenib a new anti-tumor drug.
目的合成抗肿瘤新药索拉非尼。
In the latter scenario, sorafenib should also constitute the control arm of these trials.
在近来的方案中,索拉·菲尼将成为这些实验中的控制臂。
Hepatology Digest: There is obviously a lot of talk about sorafenib at this year´s meeting.
国际肝病: 在今年的会议上有很多关于索拉菲尼的研究报道。
The SHARP trial showed that compared to placebo, people live longer if they took sorafenib.
索拉·芬妮临床研究组与安慰剂组比较起来,前者具有更长的存活时间。
Treatment duration was a median of 23 weeks in the sorafenib group and 19 weeks in the placebo group.
治疗时间中位数在索拉非尼组为23周,在安慰剂组为19周。